CTOs on the Move

Fore Biotherapeutics

www.fore.bio

 
As a leader in precision oncology, Fore Biotherapeutics provides patients with unaddressed cancer mutations new hope by connecting them with hyper-targeted medicines. Fore`s integrated functional genomics and machine learning capabilities, known as Foresight, are elucidating disease biology in competitively distinct and unparalleled ways that allow us to uniquely identify clinical-stage assets for people with few to no therapeutic alternatives. Fore is advancing its lead program, FORE8394, to treat both V600 and non-V600 BRAF mutations and continues to refine its clinical approach to serve more patient populations with difficult-to-treat mutations across oncogenes.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.fore.bio
  • 3675 Market Street
    Philadelphia, PA USA 19104
  • Phone: 215.989.4841

Executives

Name Title Contact Details
Sujit Basu
Senior Vice President and Head of Global Manufacturing and Technical Operations Profile

Similar Companies

Point Biopharma

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

Genesis Bioventures

Genesis Bioventures, Inc. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.

ChemCross.com

ChemCross.com is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ms Sarah's Creations Of Beauty

Ms Sarah's Creations Of Beauty is a Daly City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.